Atovaquone and ELQ-300 combination therapy as a novel dual-site cytochrome bc1 inhibition strategy for malaria

Allison M. Stickles, Martin J. Smilkstein, Joanne M. Morrisey, Yuexin Li, Isaac P. Forquer, Jane X. Kelly, Sovitj Pou, Rolf W. Winter, Aaron Nilsen, Akhil B. Vaidya, Michael Riscoe

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Antimalarial combination therapies play a crucial role in preventing the emergence of drug-resistant Plasmodium parasites. Although artemisinin-based combination therapies (ACTs) comprise the majority of these formulations, inhibitors of the mitochondrial cytochrome bc1 complex (cyt bc1) are among the few compounds that are effective for both acute antimalarial treatment and prophylaxis. There are two known sites for inhibition within cyt bc1: atovaquone (ATV) blocks the quinol oxidase (Qo) site of cyt bc1, while some members of the endochin-like quinolone (ELQ) family, including preclinical candidate ELQ-300, inhibit the quinone reductase (Qi) site and retain full potency against ATV-resistant Plasmodium falciparum strains with Qo site mutations. Here, we provide the first in vivo comparison of ATV, ELQ-300, and combination therapy consisting of ATV plus ELQ-300 (ATV:ELQ-300), using P. yoelii murine models of malaria. In our monotherapy assessments, we found that ATV functioned as a single-dose curative compound in suppressive tests whereas ELQ-300 demonstrated a unique cumulative dosing effect that successfully blocked recrudescence even in a high-parasitemia acute infection model. ATV:ELQ-300 therapy was highly synergistic, and the combination was curative with a single combined dose of 1 mg/kg of body weight. Compared to the ATV: proguanil (Malarone) formulation, ATV:ELQ-300 was more efficacious in multiday, acute infection models and was equally effective at blocking the emergence of ATV-resistant parasites. Ultimately, our data suggest that dual-site inhibition of cyt bc1 is a valuable strategy for antimalarial combination therapy and that Qi site inhibitors such as ELQ-300 represent valuable partner drugs for the clinically successful Qo site inhibitor ATV.

Original languageEnglish (US)
Pages (from-to)4853-4859
Number of pages7
JournalAntimicrobial Agents and Chemotherapy
Volume60
Issue number8
DOIs
StatePublished - Aug 1 2016

Fingerprint

Atovaquone
Electron Transport Complex III
Quinolones
Malaria
Antimalarials
Qi
Therapeutics
Parasites
Play Therapy
NAD(P)H Dehydrogenase (Quinone)
Inhibition (Psychology)
Plasmodium
Parasitemia
Plasmodium falciparum
Infection
Pharmaceutical Preparations
Body Weight

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology
  • Infectious Diseases

Cite this

Atovaquone and ELQ-300 combination therapy as a novel dual-site cytochrome bc1 inhibition strategy for malaria. / Stickles, Allison M.; Smilkstein, Martin J.; Morrisey, Joanne M.; Li, Yuexin; Forquer, Isaac P.; Kelly, Jane X.; Pou, Sovitj; Winter, Rolf W.; Nilsen, Aaron; Vaidya, Akhil B.; Riscoe, Michael.

In: Antimicrobial Agents and Chemotherapy, Vol. 60, No. 8, 01.08.2016, p. 4853-4859.

Research output: Contribution to journalArticle

Stickles, AM, Smilkstein, MJ, Morrisey, JM, Li, Y, Forquer, IP, Kelly, JX, Pou, S, Winter, RW, Nilsen, A, Vaidya, AB & Riscoe, M 2016, 'Atovaquone and ELQ-300 combination therapy as a novel dual-site cytochrome bc1 inhibition strategy for malaria', Antimicrobial Agents and Chemotherapy, vol. 60, no. 8, pp. 4853-4859. https://doi.org/10.1128/AAC.00791-16
Stickles, Allison M. ; Smilkstein, Martin J. ; Morrisey, Joanne M. ; Li, Yuexin ; Forquer, Isaac P. ; Kelly, Jane X. ; Pou, Sovitj ; Winter, Rolf W. ; Nilsen, Aaron ; Vaidya, Akhil B. ; Riscoe, Michael. / Atovaquone and ELQ-300 combination therapy as a novel dual-site cytochrome bc1 inhibition strategy for malaria. In: Antimicrobial Agents and Chemotherapy. 2016 ; Vol. 60, No. 8. pp. 4853-4859.
@article{d73e62283ebc425a83a9ba24eb0d2e40,
title = "Atovaquone and ELQ-300 combination therapy as a novel dual-site cytochrome bc1 inhibition strategy for malaria",
abstract = "Antimalarial combination therapies play a crucial role in preventing the emergence of drug-resistant Plasmodium parasites. Although artemisinin-based combination therapies (ACTs) comprise the majority of these formulations, inhibitors of the mitochondrial cytochrome bc1 complex (cyt bc1) are among the few compounds that are effective for both acute antimalarial treatment and prophylaxis. There are two known sites for inhibition within cyt bc1: atovaquone (ATV) blocks the quinol oxidase (Qo) site of cyt bc1, while some members of the endochin-like quinolone (ELQ) family, including preclinical candidate ELQ-300, inhibit the quinone reductase (Qi) site and retain full potency against ATV-resistant Plasmodium falciparum strains with Qo site mutations. Here, we provide the first in vivo comparison of ATV, ELQ-300, and combination therapy consisting of ATV plus ELQ-300 (ATV:ELQ-300), using P. yoelii murine models of malaria. In our monotherapy assessments, we found that ATV functioned as a single-dose curative compound in suppressive tests whereas ELQ-300 demonstrated a unique cumulative dosing effect that successfully blocked recrudescence even in a high-parasitemia acute infection model. ATV:ELQ-300 therapy was highly synergistic, and the combination was curative with a single combined dose of 1 mg/kg of body weight. Compared to the ATV: proguanil (Malarone) formulation, ATV:ELQ-300 was more efficacious in multiday, acute infection models and was equally effective at blocking the emergence of ATV-resistant parasites. Ultimately, our data suggest that dual-site inhibition of cyt bc1 is a valuable strategy for antimalarial combination therapy and that Qi site inhibitors such as ELQ-300 represent valuable partner drugs for the clinically successful Qo site inhibitor ATV.",
author = "Stickles, {Allison M.} and Smilkstein, {Martin J.} and Morrisey, {Joanne M.} and Yuexin Li and Forquer, {Isaac P.} and Kelly, {Jane X.} and Sovitj Pou and Winter, {Rolf W.} and Aaron Nilsen and Vaidya, {Akhil B.} and Michael Riscoe",
year = "2016",
month = "8",
day = "1",
doi = "10.1128/AAC.00791-16",
language = "English (US)",
volume = "60",
pages = "4853--4859",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "8",

}

TY - JOUR

T1 - Atovaquone and ELQ-300 combination therapy as a novel dual-site cytochrome bc1 inhibition strategy for malaria

AU - Stickles, Allison M.

AU - Smilkstein, Martin J.

AU - Morrisey, Joanne M.

AU - Li, Yuexin

AU - Forquer, Isaac P.

AU - Kelly, Jane X.

AU - Pou, Sovitj

AU - Winter, Rolf W.

AU - Nilsen, Aaron

AU - Vaidya, Akhil B.

AU - Riscoe, Michael

PY - 2016/8/1

Y1 - 2016/8/1

N2 - Antimalarial combination therapies play a crucial role in preventing the emergence of drug-resistant Plasmodium parasites. Although artemisinin-based combination therapies (ACTs) comprise the majority of these formulations, inhibitors of the mitochondrial cytochrome bc1 complex (cyt bc1) are among the few compounds that are effective for both acute antimalarial treatment and prophylaxis. There are two known sites for inhibition within cyt bc1: atovaquone (ATV) blocks the quinol oxidase (Qo) site of cyt bc1, while some members of the endochin-like quinolone (ELQ) family, including preclinical candidate ELQ-300, inhibit the quinone reductase (Qi) site and retain full potency against ATV-resistant Plasmodium falciparum strains with Qo site mutations. Here, we provide the first in vivo comparison of ATV, ELQ-300, and combination therapy consisting of ATV plus ELQ-300 (ATV:ELQ-300), using P. yoelii murine models of malaria. In our monotherapy assessments, we found that ATV functioned as a single-dose curative compound in suppressive tests whereas ELQ-300 demonstrated a unique cumulative dosing effect that successfully blocked recrudescence even in a high-parasitemia acute infection model. ATV:ELQ-300 therapy was highly synergistic, and the combination was curative with a single combined dose of 1 mg/kg of body weight. Compared to the ATV: proguanil (Malarone) formulation, ATV:ELQ-300 was more efficacious in multiday, acute infection models and was equally effective at blocking the emergence of ATV-resistant parasites. Ultimately, our data suggest that dual-site inhibition of cyt bc1 is a valuable strategy for antimalarial combination therapy and that Qi site inhibitors such as ELQ-300 represent valuable partner drugs for the clinically successful Qo site inhibitor ATV.

AB - Antimalarial combination therapies play a crucial role in preventing the emergence of drug-resistant Plasmodium parasites. Although artemisinin-based combination therapies (ACTs) comprise the majority of these formulations, inhibitors of the mitochondrial cytochrome bc1 complex (cyt bc1) are among the few compounds that are effective for both acute antimalarial treatment and prophylaxis. There are two known sites for inhibition within cyt bc1: atovaquone (ATV) blocks the quinol oxidase (Qo) site of cyt bc1, while some members of the endochin-like quinolone (ELQ) family, including preclinical candidate ELQ-300, inhibit the quinone reductase (Qi) site and retain full potency against ATV-resistant Plasmodium falciparum strains with Qo site mutations. Here, we provide the first in vivo comparison of ATV, ELQ-300, and combination therapy consisting of ATV plus ELQ-300 (ATV:ELQ-300), using P. yoelii murine models of malaria. In our monotherapy assessments, we found that ATV functioned as a single-dose curative compound in suppressive tests whereas ELQ-300 demonstrated a unique cumulative dosing effect that successfully blocked recrudescence even in a high-parasitemia acute infection model. ATV:ELQ-300 therapy was highly synergistic, and the combination was curative with a single combined dose of 1 mg/kg of body weight. Compared to the ATV: proguanil (Malarone) formulation, ATV:ELQ-300 was more efficacious in multiday, acute infection models and was equally effective at blocking the emergence of ATV-resistant parasites. Ultimately, our data suggest that dual-site inhibition of cyt bc1 is a valuable strategy for antimalarial combination therapy and that Qi site inhibitors such as ELQ-300 represent valuable partner drugs for the clinically successful Qo site inhibitor ATV.

UR - http://www.scopus.com/inward/record.url?scp=84979207872&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84979207872&partnerID=8YFLogxK

U2 - 10.1128/AAC.00791-16

DO - 10.1128/AAC.00791-16

M3 - Article

C2 - 27270285

AN - SCOPUS:84979207872

VL - 60

SP - 4853

EP - 4859

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 8

ER -